Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
Question
Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
Direct answer
Positive Phase III efficacy in comorbid diabetes/obesity positions survodutide as a dual glucagon/GLP-1 asset, shifting expected royalty revenues for licensor ZLDPY. — bullish pressure on ZLDPY via milestone and future commercial royalty repricing on Phase III success.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/survodutide-achieves-13-1-weight-loss-in-phase-iii-diabetes-and-obesity-trial-5a5f23
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ZLDPY | ▲Bull | 1–5 days | milestone and future commercial royalty repricing on Phase III success | 57 |
Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
Positive Phase III efficacy in comorbid diabetes/obesity positions survodutide as a dual glucagon/GLP-1 asset, shifting expected royalty revenues for licensor ZLDPY. — bullish pressure on ZLDPY via milestone and future commercial royalty repricing on Phase III success.
Zealand Pharma co-developed and licenses survodutide to Boehringer Ingelheim.
- SourceZealand Pharma co-developed and licenses survodutide to Boehringer Ingelheim.
- TransmissionPositive Phase III efficacy in comorbid diabetes/obesity positions survodutide as a dual glucagon/GLP-1 asset, shifting expected royalty revenues for licensor ZLDPY.
- SummaryPhase III SYNCHRONIZE-2 trial met primary endpoints with 13.1% weight loss at 76 weeks. Placebo arm recorded 3.1% weight reduction over the same evaluation window. Results validate dual glucagon/GLP-1 receptor agonism in comorbid obesity and diabetes.
- ZLDPYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- ZLDPY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ZLDPY price vs. pre-event level
- ZLDPY volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial · GlobeNewswire Inc. · 2026-10-01
Related catalysts
- 2026-10-01Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Survodutide Delivers Up to 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
- 2026-10-01Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes CohortZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III TrialZLDPY
- 2026-10-01Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Obesity/T2D TrialZLDPY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.